Vaxcyte (PCVX) concentration risks

The company's concentration profile is defined by two high-share supply dependencies and a medium-share pipeline risk, all of which are tightly interconnected. On the manufacturing side, the company relies on an exclusively licensed cell-free protein synthesis platform from Sutro Biopharma, Inc. — a high-share dependency on a single licensor for the core production technology. Any disruption to that relationship, whether through licensing disputes, Sutro's own operational issues, or changes in the agreement's terms, would directly impair the company's ability to produce its vaccine candidates. The manufacturing dependency extends to a sole contract manufacturer, Lonza, also a high-share reliance. With both the upstream technology platform and the downstream manufacturing capacity concentrated in single-party relationships, the supply chain carries limited redundancy at a stage when the company has not yet reached commercial revenue. Layered onto these supply constraints is a medium-share pipeline concentration: the business is highly dependent on the success of its pneumococcal conjugate vaccine candidates, which is a mixed-character exposure — partly structural (the company's explicit strategic focus) and partly idiosyncratic (clinical and regulatory outcomes that cannot be controlled). The interaction of these three exposures means that a single adverse event — a licensor disruption, a manufacturing setback at Lonza, or a clinical failure — could simultaneously threaten multiple dimensions of the business.

For the engine’s reasoning on PCVX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.